CA3129861A1 - Compose heterocyclique pentacyclique - Google Patents

Compose heterocyclique pentacyclique Download PDF

Info

Publication number
CA3129861A1
CA3129861A1 CA3129861A CA3129861A CA3129861A1 CA 3129861 A1 CA3129861 A1 CA 3129861A1 CA 3129861 A CA3129861 A CA 3129861A CA 3129861 A CA3129861 A CA 3129861A CA 3129861 A1 CA3129861 A1 CA 3129861A1
Authority
CA
Canada
Prior art keywords
mmol
diazepine
dione
added
pyrimido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3129861A
Other languages
English (en)
Inventor
Yoshiaki Ohashi
Yoshihiko Norimine
Tamaki Hoshikawa
Yu Yoshida
Yoshihisa Kobayashi
Nobuhiro Sato
Koji Hagiwara
Nobuaki Sato
Shinsuke Hirota
Takaaki Harada
Hikaru Yoshimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of CA3129861A1 publication Critical patent/CA3129861A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne un composé représenté par l'une quelconque des formules (I)-(XVII) ou un sel pharmaceutiquement acceptable de celui-ci, qui a un effet d'activation neuronale cholinergique et peut être appliqué en tant qu'agent thérapeutique pour une déficience cognitive.
CA3129861A 2019-03-05 2020-03-03 Compose heterocyclique pentacyclique Pending CA3129861A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-039351 2019-03-05
JP2019039351 2019-03-05
PCT/JP2020/008881 WO2020179780A1 (fr) 2019-03-05 2020-03-03 Composé hétérocyclique pentacyclique

Publications (1)

Publication Number Publication Date
CA3129861A1 true CA3129861A1 (fr) 2020-09-10

Family

ID=72336168

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3129861A Pending CA3129861A1 (fr) 2019-03-05 2020-03-03 Compose heterocyclique pentacyclique

Country Status (21)

Country Link
US (1) US11358972B2 (fr)
EP (1) EP3936190A4 (fr)
JP (1) JP7504864B2 (fr)
KR (1) KR20210135224A (fr)
CN (1) CN113453762B (fr)
AR (1) AR118235A1 (fr)
AU (1) AU2020232044A1 (fr)
BR (1) BR112021015975A2 (fr)
CA (1) CA3129861A1 (fr)
CL (1) CL2021002144A1 (fr)
CO (1) CO2021010512A2 (fr)
EA (1) EA202191966A1 (fr)
IL (1) IL285511B1 (fr)
JO (1) JOP20210219A1 (fr)
MA (1) MA55221A (fr)
MX (1) MX2021009685A (fr)
PE (1) PE20211978A1 (fr)
SG (1) SG11202108780PA (fr)
TW (1) TWI821537B (fr)
WO (1) WO2020179780A1 (fr)
ZA (1) ZA202105729B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202100531A (zh) 2019-03-05 2021-01-01 日商衛材R&D企管股份有限公司 五環化合物之鹽及其等之結晶

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE258234C (fr)
US4187306A (en) 1977-07-26 1980-02-05 Bayer Aktiengesellschaft Benzodiazepine-diones, a process for their production and their use as medicaments
RU2117670C1 (ru) 1988-10-31 1998-08-20 Эйсай Ко., Лтд. Производные триазоло[1,4]диазепина и способы их получения
TW197442B (fr) 1990-02-08 1993-01-01 Pfizer
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5736992A (en) * 1994-10-31 1998-04-07 Hewlett-Packard Pressure regulated free-ink ink-jet pen
KR100203456B1 (ko) 1995-06-20 1999-06-15 한승수 디하이드로에보디아민-에이치씨1를 유효성분으로 함유하는 알츠하이머병에 의한 치매 치료제
CL2004000348A1 (es) 1997-04-15 2005-01-14 Cephalon Inc & Kyowa Hakko Kog Compuesto derivado de estaurosporina bis-n-sustituida, util para potenciar la funcion de neuronas colinergicas, estriadas, del prosencefalo basal y sensoriales.
CL2004000352A1 (es) 1998-05-26 2005-05-27 Cephalon Inc & Kyowa Hakko Kog Uso de compuestos derivados de estaurosporina para potenciar la funcion de neuronas colinergicas, estriadas, de prosencefalo basal y sensoriales.
FR2779652B1 (fr) 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
DE10246207B4 (de) * 2002-10-04 2008-04-03 Disetronic Licensing Ag Mikrodialysesonde mit spiralförmiger Leitung
AU2003299378A1 (en) 2002-10-11 2004-05-04 Board Of Regents, The University Of Texas System Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
GB0308333D0 (en) * 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
CN101084220B (zh) 2004-10-20 2010-12-15 弗·哈夫曼-拉罗切有限公司 卤素取代的苯并二氮杂*衍生物
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
GB201100181D0 (en) * 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
EP3144308B1 (fr) * 2014-05-16 2020-06-24 Takeda Pharmaceutical Company Limited Composé hétérocyclique contenant de l'azote
PL3680243T3 (pl) 2017-09-07 2022-02-14 Eisai R&D Management Co., Ltd. Związek pentacykliczny
TW202100531A (zh) 2019-03-05 2021-01-01 日商衛材R&D企管股份有限公司 五環化合物之鹽及其等之結晶

Also Published As

Publication number Publication date
EP3936190A1 (fr) 2022-01-12
PE20211978A1 (es) 2021-10-05
AU2020232044A1 (en) 2021-09-02
ZA202105729B (en) 2022-08-31
CL2021002144A1 (es) 2022-02-04
CN113453762A (zh) 2021-09-28
SG11202108780PA (en) 2021-09-29
JPWO2020179780A1 (fr) 2020-09-10
TWI821537B (zh) 2023-11-11
AR118235A1 (es) 2021-09-22
JOP20210219A1 (ar) 2023-01-30
MA55221A (fr) 2022-01-12
KR20210135224A (ko) 2021-11-12
MX2021009685A (es) 2021-09-10
US11358972B2 (en) 2022-06-14
US20200283452A1 (en) 2020-09-10
TW202100528A (zh) 2021-01-01
EA202191966A1 (ru) 2021-12-08
BR112021015975A2 (pt) 2021-10-05
IL285511A (en) 2021-09-30
CN113453762B (zh) 2024-06-07
WO2020179780A1 (fr) 2020-09-10
CO2021010512A2 (es) 2021-10-29
EP3936190A4 (fr) 2022-11-16
IL285511B1 (en) 2024-06-01
JP7504864B2 (ja) 2024-06-24

Similar Documents

Publication Publication Date Title
KR100883003B1 (ko) 알츠하이머병의 치료를 위한 글라이신 수송체1(ｇｌｙｔ-1) 억제제로서 바이- 및 트라이사이클릭 치환된페닐 메탄온
JP2020502146A (ja) Ｒｉｐ１キナーゼの阻害剤及びその使用方法
CN111051316B (zh) 五环化合物
BRPI0712132A2 (pt) pirido[3,2-e] pirazinas, uso das mesmas como inibidores de fosfodiesterase 10 e processos para a preparação das mesmas
PT2356123E (pt) Espiro-5,6-di-hidro-4h-2,3,5,10b-tetra-azabenzo[ e]azulenos
CN112584898A (zh) P2x3受体拮抗剂
US20220202787A1 (en) Isothiazolidine 1,1-dioxide and 1,4-butan sultone containing rapamycin derivatives and uses thereof
RU2384581C2 (ru) ЗАМЕЩЕННЫЕ 2-АМИНО-3-СУЛЬФОНИЛ-ТЕТРАГИДРО-ПИРАЗОЛО[1,5-a]ПИРИДО-ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
US11358972B2 (en) Pentacyclic heterocycles
CN113429427A (zh) 杂环化合物及其制备方法和药物用途
RU2815382C2 (ru) Пентациклическое гетероциклическое соединение
CA2999929A1 (fr) Derives de pyridine condenses en tant qu'inhibiteurs de kinases
CN116997555A (zh) 新颖噻吩并嘧啶酮衍生物
RU2391343C1 (ru) ТЕТРАГИДРО-ПИРАЗОЛО[1,5-a]ПИРИДО-ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
CN116981673A (zh) 新颖噻二唑并嘧啶酮衍生物
TW201936614A (zh) 作為胞內體類鐸（toll-like）受體抑制劑之化合物及組合物
RU2374249C1 (ru) ЗАМЕЩЕННЫЕ ЦИКЛОАЛКАНО[е ИЛИ d]ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТ6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231219